FRACTYL HEALTH, INC.GUTSEarnings & Financial Report
Fractyl Health is a Burlington, Massachusetts-based healthcare company focused on metabolic diseases like obesity and type 2 diabetes. The company developed Revita, an outpatient endoscopic procedure to modify duodenal dysfunction, and Rejuva, a gene therapy platform in preclinical development to enable the pancreas to produce glucagon-like peptide-1 (GLP-1).
GUTS Q3 FY2024 Key Financial Metrics
Revenue
$14.0K
Gross Profit
$7.0K
Operating Profit
$-23.8M
Net Profit
$-23.2M
Gross Margin
50.0%
Operating Margin
-169957.1%
Net Margin
-165521.4%
YoY Growth
N/A
EPS
$-0.48
FRACTYL HEALTH, INC. Q3 FY2024 Financial Summary
FRACTYL HEALTH, INC. reported revenue of $14.0K for Q3 FY2024, with a net profit of $-23.2M (-165521.4% margin). Cost of goods sold was $7.0K, operating expenses totaled $23.8M.
Key Financial Metrics
| Total Revenue | $14.0K |
|---|---|
| Net Profit | $-23.2M |
| Gross Margin | 50.0% |
| Operating Margin | -169957.1% |
| Report Period | Q3 FY2024 |
FRACTYL HEALTH, INC. Quarterly Revenue & Net Profit History
FRACTYL HEALTH, INC. results over the last 3 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2024 | $14.0K | — | $-23.2M | -165521.4% |
| Q2 FY2024 | $43.0K | — | $-17.2M | -40067.4% |
| Q1 FY2024 | $33.0K | — | $-3.3M | -10066.7% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | |
|---|---|---|---|
| Revenue | $33000 | $43000 | $14000 |
| YoY Growth | N/A | N/A | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | |
|---|---|---|---|
| Assets | $163.5M | $146.4M | $126.9M |
| Liabilities | $79.3M | $75.7M | $76.6M |
| Equity | $84.2M | $70.8M | $50.3M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | |
|---|---|---|---|
| Operating CF | $-11.7M | $-18.7M | $-18.0M |